Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2010 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Neurologix Completes Additional $7 Million Financing
    5. Neurologix Announces First Quarter 2011 Financial Results
    6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
    8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
    11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
    (Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
    (Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
    Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
    ... FHC ) today announced that it has received ... Brazilian Ministry of Health. It is anticipated,that shipments will ... by UNAIDS and other global public agencies for its,highly ... pleased that Brazilian women will continue to have access ...
    ... 78% to 100% with ... Masimo,s PI measurement, IRVINE, Calif., ... Read-Through Motion and Low,Perfusion pulse oximetry, reported that a new independent ... (PI),to improve detection of congenital heart defects (CHD) in newborns with,duct-dependent ...
    Cached Medicine Technology:Female Health Company Receives Brazilian Order: Four Million FC Female Condoms 2New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns 2New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns 3New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns 4
    (Date:7/11/2014)... that an "expressive therapy" group intervention conducted by ... disclose their health status and improves their social ... their relationships., "Medication alone is totally insufficient," said ... director of the Women,s HIV Program at UCSF. ... effective antiretroviral therapy but far too many are ...
    (Date:7/11/2014)... Recently, iFitDress.com, a leading online supplier of wedding ... new collection of evening dresses for 2014. ... all these beautiful items are provided with big discounts, ... offer is July 22. , According to the ... to customer satisfaction. On the company’s website, sincere customer ...
    (Date:7/11/2014)... Organic Crop Farming in Australia ... limelight over the past decade. According to IBISWorld industry ... be an alternative food eaten only by minority groups, ... food.” Organic crop farmers have reaped the benefits of ... herbs over the past five years. Industry revenue is ...
    (Date:7/11/2014)... patients, the era of personalized medicine may be just ... Stem Cell researcher Min Yu and scientists at Massachusetts ... July 11 study in Science , Yu and ... circulating through the blood streams of six patients. Some ... metastasis, which travel to and establish secondary tumors in ...
    (Date:7/11/2014)... Alliance Labs announced that they will be ... Begley Jr, airing later this year 2014, via Discovery ... episode, Innovations will explore DocuSol® Kids, a mini-enema containing ... glycol base designed to give adolescents general constipation relief. ... a hyperosmotic laxative by drawing water into the bowel ...
    Breaking Medicine News(10 mins):Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2
    ... asked to investigate Australia’s crippled mental health services and ... that the funding would triple for Australia's mental health ... set up if the Government accepts the demands of ... release mental health patients from institutions into the community. ...
    ... long waiting lists. He said that they can take their health ... He guaranteed that one can open the door to legal action ... , By this the framework in place is maintained ... care that is essential. Clement said this while, speaking at a ...
    ... The device, which is used for treating obstructive sleep apnea ... to be beneficial in resolving heart abnormalities, says Belgium physicians. ... that pump less effectively. ,"Not only are ... side of the heart was dilated and the heart muscle ...
    ... the alleged leak of question papers of the MD/MS and ... Institute of Medical Sciences (AIIMS), // has been identified ... Medical College. ,Satish Kumar (26),an MD (Paediatric) student, ... two other doctors have been taken into custody by ...
    ... would be targeted towards controlling the spread of three ... are haunting the Asian region. Furthermore, a 'Programme for ... Action' would be launched neat year. ,The main focus ... financial constraints that prevent the realization of the sixth ...
    ... announced on Thursday about its overseas expansion of acquiring ... ,This is the fourth acquisition announced by the ... takeover of Romania's Terapia for $324 million, GlaxoSmithKline Plc's ... and assets to Senetek Plc's auto-injector device by the ...
    Cached Medicine News:Health News:Control And Prevention Of Three Diseases To Be Discussed: European Commission 2
    ... 12 L/min of Type I ultrapure water, ... Super-Q Plus System is designed to provide ... been pretreated by reverse osmosis, distillation or ... water quality which exceeds Type I ASTM/CAP/NCCLS ...
    ... for speed, stability and durability. Back-lighted ... modes, multiple units of measure, piece ... print, and GLP/GMP/ISO output including date ... Built-in, motor-driven internal calibration mass ...
    ... for speed, stability and durability. Back-lighted ... modes, multiple units of measure, piece ... print, and GLP/GMP/ISO output including date ... Touch-key calibration with external weights only ...
    ... Portable - Battery Powered (6 size AA ... conversion (g, ct, oz, ozt, GN, dwt, ... Counting and Percent Measure functions, Auto Print. ... Optional AC adapter may be ordered for ...
    Medicine Products: